VANCOUVER, BC / ACCESS Newswire / March 24, 2026 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT), a bioscience innovator specializing in advanced drug delivery systems, is pleased to announce a major advancement in its commercialization strategy, supported by a rapidly expanding global patent portfolio for its proprietary sublingual drug delivery platform. BioNxt has established a broad and defensible intellectual property position across key global markets, forming the ...

NRx Pharmaceuticals logo Key Points 2025 described as "extraordinarily pivotal": NRx said it is "in the FDA" with at least one drug it hopes could be approved this year and is operating revenue-generating clinics treating patients daily. Stockholders approved all four proposals, including the election of Chaim Hurvitz and Michael Taylor as Class I directors, an amendment to the 2021 Omnibus Incentive Plan, ratification of Weinberg & Company as auditor, and a non-binding say-on-pay vote. Management sa ...

转自：新华财经 新华财经上海3月24日电（记者 王淑娟）记者获悉，老百姓大药房连锁股份有限公司与信达生物达成战 略合作，重点就创新药物玛仕度肽（信尔美）的商业化合作达成战略共识，共同致力于代谢性疾病管理 的创新服务模式探索。 据悉，根据合作共识，双方将整合信达生物在创新研发领域的核心能力与老百姓大药房的终端网络及专 业服务体系，加速推动玛仕度肽在全国范围内零售终端的落地普及。 玛仕度肽是信达生物自主开发的减重降糖创新药。老百姓大药房拥有覆盖全国核心城市及县域市场的超 万家门店网络。双方还就供应链保障、患者服务体系搭建及市场推广策略等具体合作细节达成共识，计 划通过"门店专柜+药师培训+患者社群运营"的综合模式，打造代谢性疾病管理的行业标杆。 老百姓大药房创始人谢子龙表示："玛仕度肽的临床优势与老百姓大药房的慢病服务体系高度契合。我 们将充分整合门店资源、药师力量与数字化平台，打通创新药落地'最后一公里'，让患者不仅'用得 上'，更能'用得好、管得久'。" 编辑：林郑宏 信达生物创始人俞德超表示："老百姓大药房的渠道能力与专业服务是玛仕度肽触达患者的重要保障。 信达生物将发挥研发创新优势，与老百姓大药房在供应链 ...

Idorsia nominates three Board Directors with outstanding pharmaceutical industry, management and financial expertise for election at the Annual General Meeting 2026 on May 6, 2026All Board members – current and proposed – are committed to accelerating the growth of the company Allschwil, Switzerland – March 24, 2026Idorsia Ltd (SIX: IDIA) announces that the Board of Directors will propose three candidates for election to the Board at the upcoming Annual General Meeting of Shareholders: Natalia Misciattelli, ...

Idorsia nominates three Board Directors with outstanding pharmaceutical industry, management and financial expertise for election at the Annual General Meeting 2026 on May 6, 2026All Board members – current and proposed – are committed to accelerating the growth of the company Allschwil, Switzerland – March 24, 2026Idorsia Ltd (SIX: IDIA) announces that the Board of Directors will propose three candidates for election to the Board at the upcoming Annual General Meeting of Shareholders: Natalia Misciattelli, ...

Sustainability Day March 24, 2026 Forward-Looking Statements Forecasts and other forward-looking statements included in this document are based on information currently available and certain assumptions that the Company deems reasonable. Actual performance and other results may differ significantly due to various factors. Such factors include, but are not limited to: | Forward-looking statements: | This presentation contains forward-looking statements regarding the Company's future plans, strategies, and pe ...

NovaBay Pharmaceuticals, Inc. (NYSE:NBY) announced Monday its corporate name change to Stablecoin Development Corporation, signaling a full shift toward a cryptocurrency-focused strategy.From Pharms To CryptoThe biotech firm will also adopt a new ticker symbol, SDEV, which is expected to take effect on April 3, according to the press release.The company’s CEO, Michael Kazley, stated, “The name change to Stablecoin Development Corporation reflects our conviction that stablecoins represent the most compelling ...

NEW YORK, March 23, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Corcept Therapeutics Incorporated (NASDAQ: CORT) between October 31, 2024 and December 30, 2025, inclusive (the “Class Period”), of the important April 21, 2026 lead plaintiff deadline. SO WHAT: If you purchased Corcept common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee ar ...

Robbins LLP Urges AQST Stockholders Who Lost Money Investing in Aquestive Therapeutics, Inc. to Contact the Firm for Information About Leading the Class Action Accessibility StatementSkip Navigation SAN DIEGO, March 23, 2026 /PRNewswire/ -- Robbins LLPreminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Aquestive Therapeutics, Inc. (NASDAQ: AQST) securities between June 16, 2025 and January 8, 2026. Aquestive is a pharmaceutical company committed ...

Robbins LLP Urges SLNO Stockholders Who Lost Money Investing in Soleno Therapeutics, Inc. to Contact the Firm for Information About Leading the Class Action Accessibility StatementSkip Navigation SAN DIEGO, March 23, 2026 /PRNewswire/ -- Robbins LLPreminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Soleno Therapeutics (NASDAQ: SLNO) common stock between March 26, 2025 and November 4, 2025. Soleno is a pharmaceutical company focused on developing ...